6-substituted quinazoline derivative, preparation method and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A quinazoline and derivative technology, applied in the field of medicinal chemistry, can solve the problems of increasing the difficulty of curing and the probability of recurrence
Inactive Publication Date: 2011-06-01
TIANJIN INSTITUTE OF PHARMA RESEARCH
View PDF5 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
If the receptors of cancer cells are overexpressed or overactivated, the cancer cells will gro
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 16-
[0024] The preparation of embodiment 16-iodoquinazolin-4-ketone III
[0025] 2-Amino-5-iodobenzoic acid (105.2g, 0.40mol) and methyl imidium acetate (83.2g, 0.80mol) were added to 1000mL of glycerol, heated to dissolve, and a large amount of white solids precipitated after half an hour. Cool and filter to obtain 93.5 g of white solid 6-iodoquinazolin-4-one III, yield 86.1%, m.p.135-136°C; 1 H NMR (400MHz, DMSO): δ7.43-8.37 (m, 4H, ArH), 12.36 (s, 1H, ArH). ESI-MS: m / z 273 [M+H] + .
Embodiment 24-
[0026] The preparation of embodiment 24-chloro-6-iodoquinazoline IV
[0027] Dissolve 6-iodoquinazolin-4-one (93.5g, 0.34mol) in DMF (300mL), add thionyl chloride dropwise, and heat to reflux for 3h. The solvent was evaporated, and ethyl acetate was recrystallized to obtain 4-chloro-6-iodoquinazoline IV (90.2 g, 90.5%) as a white solid, m.p.165-167°C; 1 H NMR (400MHz, DMSO): δ7.43-8.37 (m, 4H, ArH). ESI-MS: m / z 291 [M+H] + .
Embodiment 3
[0028] The preparation of embodiment 32-chloro-4-(6-iodoquinazoline-4-amino)phenol V
[0029] 4-Chloro-6-iodoquinazoline (90.2 g, 0.31 mol) and 4-amino-2-chlorophenol (44.5 g, 0.31 mol) were dissolved in isopropanol (500 mL), and heated to reflux for 2 h. After the solution was cooled, it was filtered, washed with isopropanol and ether, and dried to obtain 2-chloro-4-(6-iodoquinazoline-4-amino)phenol V (112.8g, 91.3%), m.p.143-144°C; 1 H NMR (400MHz, DMSO): δ4.03 (s, 1H, NH), 7.43-8.37 (m, 7H, ArH), 10.31 (s, 1H, OH). ESI-MS: m / z 398 [M+ H] + .
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention belongs to the technical field of pharmaceutical chemistry and discloses quinazoline derivatives as shown in a general formula (I), wherein the R1 and R2 are defined by the specification. The invention also discloses a preparation method for the derivatives, physiologically acceptable salts formed by the derivatives and inorganic or organic acid or alkali as well as a pharmaceutical composition containing the derivatives and the physiologically acceptable salts. The compounds have the valuable pharmacological properties, especially the inhibitory effect on the signal transduction caused by tyrosine kinase. The invention also discloses a method for treating diseases, especially treating diseases which have the characteristic of abnormal erbB family protein tyrosine kinase (PTK) activity.
Description
technical field [0001] The invention belongs to the field of medicinal chemistry, and specifically relates to a class of novel quinazoline derivatives or pharmaceutically acceptable salts thereof, a method for preparing said quinazoline derivatives, and pharmaceutical compositions containing these compounds in the preparation of anti-inflammatory drugs. Use in tumor medicine. Background technique [0002] Tyrosine Kinase Inhibitor mainly acts on epidermal growth factor receptor (EGFR). EGFR has an important influence and control correlation on the growth of cancer cells. If the receptors of cancer cells are overexpressed or overactivated, the cancer cells will grow in large numbers, thereby increasing the difficulty of curing and the probability of recurrence. EGFR receptors can be divided into four types of human epidermal growth factor receptors (Human Epidermal Receptor). The first type is usually called EGFR, the second type is called HER2, and the other types are thi...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more